Soft robotic simulator of heart function and disease

A soft robotic simulator using 3D printing and thermal forming recreates heart anatomy and function, addressing the limitations of current simulators by accurately simulating heart diseases, enhancing device testing and surgical planning, and reducing animal testing.

WO2024233535A1PCT designated stage expired Publication Date: 2024-11-14MASSACHUSETTS INST OF TECH +2
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028128
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-07
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current cardiovascular simulators fail to accurately replicate the complex three-dimensional motion and internal structures of the heart, limiting their ability to simulate heart diseases like aortic stenosis and hindering the development of personalized treatment strategies.

Method used

A soft robotic simulator of heart function and disease is developed using 3D printing and thermal forming, combining a biorobotic right ventricle with a mock circulatory loop to recreate hemodynamics and anatomical details, allowing for patient-specific simulations of heart conditions such as pulmonary arterial hypertension and aortic valve diseases.

Benefits of technology

The simulator effectively replicates right heart flow, pressures, and volumes, enabling device testing, surgical planning, and reducing the need for animal testing, while providing a platform for developing tools to correct heart function and bridge benchtop to preclinical testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000019
    Figure 000019
  • Figure 000020
    Figure 000020
  • Figure 000021
    Figure 000021
Patent Text Reader

Abstract

A soft robotic, 3D-printed simulator of heart function and disease has been designed to recreate the anatomy and function of specific people and patients with heart disease, for use personalized cardiovascular medicine. Using clinical imaging data, this system re-creates the anatomy of the left ventricle (the main pumping chamber of the heart) and of the aorta (the main blood vessel in the body). A soft robotic heart sleeve recapitulates the pumping action of the heart during normal physiology and disease. A soft robotic aortic sleeve can be added to the system to recapitulate disease of the aortic valve (separating the left ventricle and the aorta).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] SOFT ROBOTIC SIMULATOR OF HEART FUNCTION AND DISEASE

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of and priority to U.S.S.N. 63 / 500,848, filed on May 8, 2023, which is incorporated by reference herein in its entirety.

[0004] STATEMENT REGARDING

[0005] FEDERALLY SPONSORED RESEARCH

[0006] This invention was made with government support under CBET1847541 awarded by the National Science Foundation. The government has certain rights in the invention.

[0007] FIELD OF THE INVENTION

[0008] The present invention is generally in the field of cardiovascular simulators, and more specifically a soft robotic heart mimicking heart motion and biomechanics for use in studying heart disease and treatment thereof.

[0009] BACKGROUND OF THE INVENTION

[0010] Aortic stenosis (AS) is an obstruction of blood flow through the aortic valve mediated by calcification and inflammatory processes, often caused by congenital aortic valve defects. Owing to the association between age and AS and the progressive ageing of the population, the global prevalence of AS has increased from approximately 2 to 9 million in the past three decades. Correspondingly, global deaths rose from 50 thousand to 120 thousand in the same period. If untreated, AS can result in heart failure and sudden death.

[0011] High-fidelity in vivo models of AS may advance the development of risk stratification frameworks to guide the management of AS in patient groups for whom interventional guidelines remain heterogeneous, including (1) asymptomatic patients with severe dynamic markers of AS and (2) symptomatic patients with mildly abnormal hemodynamics. The development of high-fidelity models of AS may eventually pave the way towards personalized AS management, improving perioperative mortality rates of AS interventions and patient outcome. The majority of in vivo models of AS use rigid bands or inflatable cuffs around the ascending aorta to induce left ventricular (LV) pressure overload. These devices can only achieve simple concentric-like constriction of the aorta and fail to re-create the com- plex three-dimensional (3D) flow patterns observed in AS created by maladaptive geometry from calcification or congenital defects of leaflet valves. Moreover, their limited control prevents them from recapitulating the hemodynamics of congenital aortic valve defects, which often accelerate the onset and progression of AS as well as aortic remodelling, potentially leading to other complications including aortic aneurysms, dissection and regurgitation.

[0012] There is an unmet clinical need for a high-fidelity benchtop cardiac model for device testing, interventional training, and procedure demonstration. Currently, in most in vitro cardiac simulators, the heart is represented by electromechanical displacement pumps, pneumatic semi-rigid pulse duplicator systems, synthetic hearts or organic ex-vivo components. While pumps, pulse duplicators, and synthetic hearts, which are typically silicone- or urethane-based anatomical models, have utility for well- regulated, repeatable experimental conditions, their biofidelity is limited owing to a lack of correct intracardiac anatomical details necessary for evaluating the function, and simulating the placement of intracardiac devices, such as transcatheter valve replacements, other cardiac valvular prostheses, occluder devices, interatrial shunt devices, or mechanical circulatory support strategies. Although a realistic representation of cardiac anatomy is achievable by using ex vivo beating heart model, the set-up process can be long and tedious, and the ex vivo heart tissue has limited longevity (< 1 day) due to muscle stiffening and decay. Owing to these drawbacks, in vivo animal models are commonly used in industry to test the mechanical performance of intracardiac devices, involving significant experimental cost and time.

[0013] Entirely biological approaches to recreating the heart in the field of cardiac tissue engineering range from using induced pluripotent stem cells (Macqueen, et al. Nat. Biomed. Eng. 2, 930-41 (2018)), bioprinting cell- seeded artificial scaffolds (Zhang, et al. Ann. Biomed. Eng. 45, 148-63 (2017;Hinton, et al. Sci. Adv. 1, (2015)) to decellularized heart tissues (Moser, et al. Curr. Opin. Organ Transplant. 19, 603-9 (2014)). There are remaining challenges.

[0014] The heart is a uniquely challenging organ to recreate due to its dynamic three-dimensional motion and its complex internal cardiac structures. Engineering approaches to making realistic beating heart models include the use of soft robotics and tissue engineering. Recent advances in soft robotics have demonstrated success in replicating complex biological motions at the macroscale (Roche, et al. Adv. Mater. 26, 1200-6 (2014); Roche, et al. Proc. ASME Des. Eng. Tech. Conf. 5A,2015 ; Marchese, et al. Soft Robot. 1, 75-87 (2014); Martinez, Adv. Mater. 25, 205-12 (2013); Rus et al. Nature. 521, 467-75 (2015)). Roche et al. 2015 demonstrated physiological cardiac motion by programming linear pneumatic artificial muscles (PAMs) in a soft matrix. This simplified cardiac simulator, however, lacks anatomical intracardiac structures (such as papillary muscles, chordae tendineae, ventricular trabeculae, valves and moderator bands). These features are challenging to implement with currently available synthetic materials and manufacturing methods at the submillimeter resolution (Truby et al. Nature. 540, 371-8 (2016); Wallin, et al. Nat. Rev. Mater. 3, 84-100 (2018)).

[0015] It is therefore an object of the present invention to provide a functional synthetic material-based heart mimicking device for modeling heart and cardiovascular defects and disease.

[0016] SUMMARY OF THE INVENTION

[0017] A soft robotic simulator of heart function and disease has been designed to recreate the anatomy and function of specific people and patients with heart disease, for use in personalized cardiovascular medicine. The stimulator is made using a combination of techniques such as three dimensional (3D) printing and thermal forming.

[0018] This cardiovascular simulator combines a biorobotic right ventricle (RV) and a mock circulatory loop to replicate physiology and function in vitro. The robotic right ventricle (RRV) is the primary pump, recreating the corresponding hemodynamics and obviating the need for an external pulsatile pump, and comprises organic endocardial tissue and a synthetic soft robotic myocardium. By optimizing the biomechanics and hemodynamics of the RRV through computational design and validating the simulator through an in vivo porcine study, it was shown that the system successfully replicated right heart flow, volumes and pressures on the bench and had comparable functional parameters to in vivo porcine data. By adjusting circuit parameters and actuation of individual soft robotic actuators, a diverse range of RV dysfunction, including pulmonary arterial hypertension (PAH), tricuspid valve regurgitation (TR) and RV wall myocardial infarction, could be simulated. Furthermore, the surgical replacement of a pathological TV could be simulated and post-repair hemodynamics evaluated, demonstrating the utility of the simulator for device testing, technology development and surgical planning. The RRV can also simulate the contractile motion of papillary muscles, accurately recreating tunable chord tension in both healthy and diseased conditions. Practical utility of the RRV includes improving recognition of RV (dys)function, decreasing the volume of animal testing, establishing a platform for developing tools for disease correction and bridging the gap between benchtop and preclinical testing.

[0019] Using clinical imaging data, this system re-creates the anatomy of the left ventricle (the main pumping chamber of the heart) and of the aorta (the main blood vessel in the body). The design may be patient-specific or generalized to a specific disorder. A soft robotic heart sleeve recapitulates the pumping action of the heart during normal physiology and disease. A soft robotic aortic sleeve can be added to the system to recapitulate disease of the aortic valve (separating the left ventricle and the aorta). The system can be re-adapted to simulate the pumping of the left and / or right ventricle in physiology and disease, other cardiac valves, the pulmonary artery and the more distal vasculature.

[0020] BRIEF DESCRIPTION OF THE DRAWINGS

[0021] FIGs. 1A-1C show the RRV and its architecture. Initially, a freshly explanted porcine heart underwent chemical treatment, after which the native myocardium was hand-dissected and replaced with a robotic counterpart while preserving the endocardial scaffold. FIGS. 1A-1C are micro-CT images of the assembly of the RRV, revealing the preserved intracardiac structures: 1A, intact intracardiac structures, silicone matrix, RV free wall and soft robotic myocardium. IB, soft robotic myocardium, silicone matrix and soft robotic myocardium around the RV. 1C, soft robotic myocardium around RV and silicone matrix.

[0022] FIGs. 2A-2E are schematics of the RV’s complex shape, fiber orientation and wall motion. FIG. 2A, transverse muscle orientation in RV free wall of the basal loop; oblique muscle orientation (interventricular septum) in the apical loop. FIG. 2B, arrows showing direction of muscle orientation in RV and LV of the heart. FIG. 2C and 2D, showing the muscular architecture of the LV (FIG. 2C) and crescentic non-ellipsoidal RV (FIG. 2D); FIG. 2E showing an image of the heart showing fiber orientation in the basal and apical loops, reprinted from Buckberg, et al., with permission from Elsevier.

[0023] FIGs. 3A and 3B show the placement of the individual actuators in the synthetic myocardium, showing the RV free wall and septal actuators, with mock LV (3A) and infundibular actuator (3B). The outflow tract of the RV contains infundibular muscles that also contribute to RV ejection through contraction. The contraction of the outflow region can be achieved by placing a circumferential actuator across the infundibulum. The numbers denote the respective actuator placement corresponding to the RV motion shown the schematics on the left. SVC, superior vena cava.

[0024] FIGs. 4A-4C are perspective views of the soft 3D-printed anatomical model (FIG. 4A), the heart sleeve (FIG. 4B), and the aortic sleeve (FIG. 4C).

[0025] FIGs. 5A-5B. Fig. 5A is a schematic of the entire loop illustrating the 3D-printed patient-specific anatomy of the left ventricle (LV) and aorta, the heart (LV) sleeve, the aortic sleeve, the outflow flowmeter (Qout), the arterial resistance (Ra) and compliance (Ca), the venous resistance (Rv) and compliance (Cv), the inflow flowmeter (Qin), and the mitral valve (MV). FIG. 5B is an illustration of the physical loop, illustrating the components listed above, as well as the LV and aortic actuation lines, the catheter and camera insertion points, and the reservoir.

[0026] FIGs. 6A-6F are graphs showing the in vitro and in silico characterization of the biomimetic soft robotic aortic sleeve. FIG. 6A, Axial force exerted by the bio-inspired soft robotic aortic sleeve versus actuation volume and pressure. Error bars, s.d.; n = 3 for each data point. FIGs. 6B-6E are the global hemodynamics predicted in vitro and in silico at baseline (BL) and at various actuation pressures, including EOA (6B) (n = 3), APmax (6C), APmean (6D) and LVPmax (6E). Error bars, s.d.; n = 5 actuation cycles for each data point. FIG. 6F shows representative PV loops obtained in silico. Y-axis and X-axis represent the LV pressure (LVP) and LV volume (LVV), respectively.

[0027] DETAILED DESCRIPTION OF THE INVENTION

[0028] Preclinical models of aortic stenosis can induce left ventricular pressure overload and coarsely control the severity of aortic constriction. However, they do not recapitulate the hemodynamics and flow patterns associated with the disease. A customizable soft robotic aortic sleeve that can mimic the hemodynamics and biomechanics of aortic stenosis has been developed. By allowing for the adjustment of actuation patterns and bloodflow dynamics, the robotic sleeve recapitulates clinically relevant hemodynamics in a porcine model of aortic stenosis, as confirmed via in vivo echocardiography and catheterization studies, and a combination of in vitro and computational analyses. Using in vivo and in vitro magnetic resonance imaging, the four-dimensional blood-flow velocity profiles associated with the disease and with bicommissural and unicommissural defects re-created by the robotic sleeve were quantified. The design of the sleeve, which can be adjusted on the basis of computed tomography data, allows for the design of patient-specific devices that may guide clinical decisions and improve the management and treatment of patients with aortic stenosis.

[0029] I. Definitions

[0030] As used herein, “aortic stenosis” is an obstruction of blood flow through the aortic valve mediated by calcification and inflammatory processes, often caused by congenital aortic valve defects.

[0031] As used herein, “intracardiac” refers to situated within, occurring within, introduced into, or involving entry into the heart, such as intracardiac surgery using an intracardiac catheter.

[0032] As used herein, “synthetic myocardium” refers to cardiac muscle tissue-mimic or -substitute made out of soft synthetic matrix and / or containing actuatable components, such as pneumatic artificial muscles. As used herein, “soft” refers to material mechanical properties with low modulus similar to most biological tissues in the range of 10 kPa to 10 MPa.

[0033] As used herein, physiological hemodynamics means development of intraventricular pressures simultaneously with the reduction of ventricular volumes induced by the robotic actuation of the synthetic myocardium (i.e. high pressure / low volume as opposed to high pressure / high volume in other simulators).

[0034] As used herein, “complex three-dimensional cardiac motion” and “physiological level of contractile motion” refer to three-dimensional contraction of the synthetic myocardium, resulting in the reduction of volume / volumes in one or more of the ventricular chambers (which may be left or right only).

[0035] As used herein, the left ventricle refers to the main pumping chamber of the heart, and the aorta refers to the main blood vessel in the body.

[0036] II. Soft Robotic, 3d-printed simulator of heart function and disease

[0037] The system is composed of soft 3D-printed and / or thermal replicas of heart chambers, valves, and vessels connecting thereto, which can be made patient specific or generalized to specific diseases or disorders. An example of a simulator of an individual patients’ left ventricle, aorta (ascending aorta, aortic arch, and descending aorta), a heart sleeve, and an aortic sleeve is shown in FIGs. 1A-1C, 2A-2E and 3A-3B.

[0038] This system can be used with clinical data, including CT, echocardiograpy, and catheterization data, obtained from AS patients. The CT images segmented and he segmented images used to create 3D anatomic models of patients' LV and aortas (FIG. 1A, IB), which were 3D printed with a soft elastomeric photopolymer resin (FIG. 1C). CT images were used to design patient-specific soft robotic LV and aortic sleeves.

[0039] FIGs. 1A-1C show the RRV and its architecture. Initially, a freshly explanted porcine heart undergoes chemical treatment, after which the native myocardium is hand-dissected and replaced with a robotic counterpart while preserving the endocardial scaffold. FIGS. 1A-1C are micro-CT images of the assembly of the RRV, revealing the preserved intracardiac structures: 1A, intact intracardiac structures, silicone matrix, RV free wall and soft robotic myocardium. IB, soft robotic myocardium, silicone matrix and soft robotic myocardium around the RV. 1C, soft robotic myocardium around RV and silicone matrix.

[0040] FIGs. 2A-2E are schematics of the RV’s complex shape, fiber orientation and wall motion. FIG. 2A shows the transverse muscle orientation in RV free wall of the basal loop; oblique muscle orientation (interventricular septum) in the apical loop. FIG. 2B, arrows showing direction of muscle orientation in RV and LV of the heart. FIG. 2C and 2D, showing the muscular architecture of the LV (FIG. 2C) and crescentic non- ellipsoidal RV (FIG. 2D), and image of the heart showing fiber orientation in the basal and apical loops (FIG. 2E).

[0041] This highly tuneable biomimetic soft robotic aortic sleeve is composed of three expandable elements or pockets, each connected to one actuation line. An inelastic fabric sheet spanning across the base of the soft actuator restrains the expansion of the pockets to one direction under pressure, and a slit and strip mechanism allows positioning around the outer wall of the porcine aorta. The expandable bladder is made of two vacuum- formed sheets of thermoplastic polyurethane (TPU) and a TPU-coated nylon fabric is used as the constraining layer. Other materials with comparable processing and performance parameters could be used. A positive and a negative mould of the bladder are made for vacuum-forming and sealing of the expandable elements, respectively.

[0042] The concept and design of the soft robotic aortic sleeve is based on the following: First, a high-fidelity in vivo model of AS is based on a biomimetic soft robotic aortic sleeve. The tunability of the sleeve enables the re-creation of the hemodynamics of AS and of congenital valve abnormalities, including those of bicommissural and unicommissural aortic valves. Second, two TPU sheets are vacuum formed to a 3D-printed mould. Third, the two TPU sheets are heat sealed together, creating three distinct expandable pockets which are then attached to a strain-limiting fabric through a heat-sealing process that uses a negative of the 3D-printed mould.

[0043] The components of the heart stimulator can be made using 3D printing and / or thermal molding. The anatomical replicas can be printed with a wall thickness of between 1.0 and 1.5 mm using a 3D-printing photopolymer resin (for example, Elastic 50A; Formlabs, Somerville, MA on a Form 3B Stereolithography (STL) 3D-printer (Formlabs) with a layer thickness of 0.1 mm).

[0044] The heart sleeve is composed of four inflatable pockets made of two layers of thermoplastic polyurethane (0.2-0.4 mm thick) that are formed to the shape of each individual anatomical replica, as obtained via medical images. The edges of these four pockets are heat-sealed to a thin (0.1 -0.3 mm) inextensible fabric layer which helps direct the expansion of these pockets inwards rather than outwards during pressurization, enabling contraction of the heart model. A 3D-printed (Objet30, Stratasys) rigid skeleton with four arms (one for each pair of adjacent pockets of the LV sleeve) secures each patient-specific LV sleeve to the corresponding 3D- printed geometry. Actuation lines are connected to the pockets (one line per pocket) for pressurization.

[0045] FIGs. 3A and 3B show the placement of the individual actuators in the synthetic myocardium, showing the RV free wall and septal actuators, with mock LV (3A) and infundibular actuator (3B). The outflow tract of the RV contains infundibular muscles that also contribute to RV ejection through contraction. The contraction of the outflow region can be achieved by placing a circumferential actuator across the infundibulum. The numbers denote the respective actuator placement corresponding to the RV motion shown the schematics on the left. SVC, superior vena cava.

[0046] FIGs. 4A-4C are perspective views of the soft 3D-printed anatomical model (FIG. 4A), the heart sleeve (FIG. 4B), and the aortic sleeve (FIG. 4C).

[0047] The aortic sleeve is made of three inflatable pockets, each mimicking one leaflet of the aortic valve. When simulating bicuspid aortic disease (a congenital defect of the aortic valve when two of the three leaflets are fused together), the aortic sleeve is made of two pockets. The number of pockets can be customized to recreate patient-specific defects. The pockets of the aortic sleeves are shaped to the native aortic leaflet geometry of each individual patients, as obtained via medical images. Akin to the heart sleeve, these pockets are heat sealed to a thin fabric layer and connected to actuation lines. The anatomical replicas are then connected to a standard closed-loop flow system without an external pump as the pulsatile action is provided by the heart sleeve (FIGs. 5A-5B). The heart and aortic sleeve(s) are both connected to an electropneumatic system for actuation. The rest of the loop consists of a soft polyvinyl chloride (PVC) plastic tubing, two variableresistance ball valves to mimic arterial and venous resistance, two acrylic compliance chambers to recreate peripheral compliance, and a unidirectional mechanical valve to mimic the function of the mitral valve. An illustration of the loop is provided in FIG. 5B.

[0048] The soft robotic sleeve can be actuated under hydraulic quasi-static volume-control conditions or under pneumatic dynamic pressure control. Both quasi-static and dynamic actuations allow us to recapitulate the hemodynamics of LV pressure overload. However, while quasi-static actuation is better suited to create longitudinal models of progressive pressure overload, dynamic control enables high-fidelity biomechanical and hemodynamic mimicry of a stenotic aortic valve and is therefore poised to create pressure overload models secondary to AS. Further, patient-specific aortic flow patterns can be re-created with enhanced accuracy compared with other models. By enabling actuation dynamics and pressure levels independently for each pocket of the sleeve during both systole and diastole, the biomimetic sleeve allows the re-creation of a variety of kinematics of stenotic aortic valves that could be relevant for preclinical and translational studies of human physiology and disease.

[0049] The soft robotic LV sleeve provided the contractile force necessary to generate patient-specific systolic pressure and flows as well as modulation of LV compliance seen in the spectrum of pressure overload, while the soft robotic aortic sleeve provided morphologic mimicry and recapitulation of patient- specific hemodynamics. This personalized model enables testing of hemodynamic changes induced by TAVR and other devices under different conditions.

[0050] As shown in FIG. 6A-6E, hemodynamic parameters relevant in AS were measured using pressure-volume catheters, an endoscopic camera, and continuous-wave and color flow mapping echocardiography. FIG. 6A illustrates the mean trans valvular gradient (DPmean) for n=13 different patients obtained using our tunable soft robotic system, validated through a comparison with non-dynamic 3D printing methods. In another work, using a generalized design of the aortic sleeve, we demonstrate that we are able to visualize flow patterns in the MRI environment, as shown in FIG. 6B. This image illustrates spatiotemporal changes in flow vectors, as well as the geometry of the constriction, induced by the soft robotic aortic sleeve. FIG. 6C-D illustrates that modulation of the LV compliance can be achieved via tuning of the diastolic pressure of the LV sleeve, therefore resulting in various slopes of the end-diastolic pressure- volume relationship (EDPVR) curve, as associated with physiologic and pathophysiologic conditions. FIG. 6D-6F depicts changes in the hemodynamics resulting (DPmean) from implantation of a TAVR in the system and other metrics including EOA, DPmax, vmax, LVPs, LVEDP, SV, and LVEF pre- and post-intervention.

[0051] Preliminary data includes n = 11 patients with degenerative aortic stenosis, n = 2 with BAV, n = 1 moderate diastolic dysfunction, and n = 1 with severe diastolic dysfunction. A soft robotic LV was integrated into the system with 40 60 80 100 120 140 160 180 LVV (mL) secondary loss of LV compliance and impaired filling. The robotic sleeves followed similar design and manufacture workflows as the aortic sleeve previously used in acute animal studies of AS. To enable patient-specific hemodynamic mimicry, clinical data, including computed tomography (CT) and hemodynamic evaluation of patients with AS or HFpEF, was used. Using CT data from patients at the Massachusetts General Hospital, DICOM images (Materialise Mimics) were segmented to extract LV and aortic geometries specific to each patient. These were converted into stereolithography files for 3D printing. Flexible materials (hardness 50A, Formlabs, Somerville, MA), with a similar elastic modulus to native tissue were used. Patient-specific LV and aortic sleeves can be designed and made to match each patient’ s LV and aortic geometries, using manufacturing techniques including vacuum forming of thermoplastic polyurethane (TPU) sheets using a 3D-printed positive mold, heat sealing two sheets of TPU together using a negative mold to create an inflatable bladder, which is connected to lines to provide pneumatic pressure for actuation. Next, an inextensible TPU- coated layer is heat sealed to one side of the bladder to constrain its motion and ensure optimal force transmission in the correct direction (i.e., towards the aorta for aortic compression and towards the LV for cardiac contraction). Customized molding is used to accurately fit the LV sleeve around the patient-specific 3D-printed model of the heart, enabling adjustment of compliance as well as mimicry of the morphology of lesions (for AS) to recreate patient-specific flow patterns across the aortic valve. The accuracy of the morphologic mimicry of the AS is assessed by comparing images from an endoscopic camera and CINE data of aortic valve kinematics. DICE similarity score is used as a metric of success. The actuation of the sleeves is tuned to match the patients’ hemodynamics measured by transesophageal echo (TEE) or catheterization. Particularly, the actuation pressure provided to the LV sleeve will be adjusted to recreate the patient’s LV compliance and filling performance during relaxation and LV contractility during systole. The end- diastolic and end-systolic LV diameters, the stroke volume, and the ejection fraction are measured for validation of the model. Analogously, actuation of the aortic sleeve is controlled to recapitulate the effective orifice area (EOA), maximum (APmax) and mean (APmean) transaortic pressure gradients, and the peak ejection velocity (vpeak), defining the severity of AS and pressure overload driving loss of LV compliance and diastolic dysfunction.

[0052] III. Methods of Use

[0053] Loss of left ventricular (LV) compliance is associated with several cardiovascular conditions. It can arise due to genetic or immune mechanisms or from remodeling processes secondary to LV pressure overload, including aortic stenosis (AS) or hypertension. Stiffening of the LV and the resulting inability of the heart to fill adequately are the main biomechanical and hemodynamic manifestations of a variety of diseases, including hypertrophic (HCM)8 and restrictive cardiomyopathies (RCM) (e.g., endomyocardial fibrosis, amyloidosis, sarcoidosis, hemochromatosis), often leading to symptoms of heart failure, specifically heart failure with preserved ejection fraction (HFpEF) - a complex and multifaceted condition affecting over 13 million people worldwide and accounting for approximately 50% of all cases of heart failure. While it is known that LV pressure overload (e.g., from aortic stenosis and hypertension) can drive remodeling processes of the LV, and therefore loss of compliance, the fundamental mechanisms underlying the progression and plasticity, or potential reversibility, of these processes are not yet fully understood. Further, the heterogeneity in phenotypes leads to a lack of effective treatments or medical devices that can restore adequate hemodynamics in these patients.

[0054] Owing to a broad diversity of etiologies, comorbidities, and phenotypes, the development of effective therapeutics and devices to support healthy ventricular filling has been hindered. Large-scale clinical trials of pharmacologic therapies have had mixed results and have failed to conclusively show reductions in mortality, resulting in a mere -35% survival rate from the onset of symptoms of heart failure. Analogously, although implantable mechanical circulatory support (MCS) devices and other device- based solutions have been successfully developed for other conditions (e.g., heart failure with reduced ejection fraction or HFrEF), there is currently no FDA-approved device-based solution that can enhance cardiac filling.

[0055] The efforts made towards the development of medical devices that can enhance cardiac mechanics in HFpEF patients have been largely hindered by the absence of reliable hemodynamic in vivo models, leading to the lack of FDA-approved device-based solutions for this condition. Most of the functional evaluation of HFpEF devices report testing on healthy in vivo models and unanimously emphasize the inability to simulate HFpEF hemodynamics as the primary limitation of their studies. The development of high-fidelity models that can recapitulate the biomechanics of loss of LV compliance and associated hemodynamics represents a critical step towards the development of mechanical solutions for this condition. By developing an enhanced, sensorized, and highly controllable in vivo model of pressure overload, one can reliably recapitulate a spectrum of hemodynamic phenotypes of HFpEF and to pave the way towards chronic studies to help us answer fundamental questions regarding the progression of cardiac remodeling, the plasticity, and the potential for reversibility of these processes. An enhanced recapitulation and understanding of the biomechanics of pressure overload on LV remodeling is a crucial tool for developing therapeutic strategies to prevent or reverse disease progression. High-fidelity models will allow personalized treatment plans targeted to each individual patient, and ultimately improve the quality of life of these patients by ameliorating their symptoms and supporting cardiac function.

[0056] In addition to normal physiologic function, either generalized or patient- specific created using medical imaging, this system can be tuned to re-create conditions such as reduced pumping and filling function of the heart (through modulation of the soft robotic heart sleeve), which are observed in patients with heart failure. Heart failure affects over 6 million people in the United States and 26 million people worldwide. The system can simulate the hemodynamics of other conditions, including hypertrophic and restrictive cardiomyopathies.

[0057] The system can simulate aortic valve disease, such as aortic stenosis (both degenerative and congenital), which is the narrowing of the aortic valve orifice due to reduced mobility of the valve leaflets and affects 1.5 million people in the United States and over 16 million people globally. Other cardiovascular conditions can be simulated using our system, including aortic dissection, aortic aneurysm, mitral valve stenosis and regurgitation.

[0058] By recreating patient-specific anatomies, physiologies, and disease states, this system can:

[0059] Support studies of hemodynamics

[0060] Support medical device companies in the development of advanced therapies (such as heart pump and cardiac valve prostheses) for these conditions

[0061] Support testing of existing and new devices for edge-case conditions, such as complex cardiac and valvular anatomies and particularly abnormal hemodynamics

[0062] Support personalized interventional planning and clinical decisions regarding device selection and implantation

[0063] Support educational training of medical students, residents, interventionalists on cardiac anatomy and function, and medical device delivery or implantation.

[0064] The main advantages of these models involve the ability to:

[0065] Recreate patient-specific anatomies in a time- and cost-efficient manner using 3D-printing techniques enables manufacturing of patient- specific anatomies with high accuracy and efficiency compared to other techniques such as injection molding.

[0066] Recreate patient-specific cardiac function without an additional pulsatile pump

[0067] Traditional hydrodynamic models leverage displacement-control pumps, which eject a prescribed amount of volume into the circulation, which are not representative of cardiac physiology. By means of the soft robotic cardiac sleeve, this system can simulate cardiac contraction in a more physiologic way.

[0068] Recreate patient-specific hemodynamic disease states (heart failure and aortic valvular disease among others)

[0069] Because of their physiologically inaccurate pumping mechanism, traditional systems fail to recapitulate changes in cardiac relaxation or filling which may be associated with heart failure. By using a tunable soft robotic heart sleeve, systolic and diastolic pressures can be modulated to recreate the exact blood pressures and flows of any given patient during any part of the cardiac cycle.

[0070] In summary, a benchtop model has been developed that can recapitulate the hemodynamics of these conditions, allowing for accurate mimicry of the aortic lesion, as well as acute and chronic changes in LV compliance. This system is fully tunable, can mimic congenital defects and can enable recapitulation of changes in cardiac function including loss of LV compliance and impaired filling. Validation of this model with clinical data pre- and post-intervention supports its use i) as a training tool, ii) as a platform for the development and testing of medical devices, and iii) as a tool for interventional planning and hemodynamic outcome prediction. The performance of the aortic sleeve is acceptable for benchtop, computational and sub-acute animal studies.

[0071] Thee mechanical behaviour and hemodynamic effects of the biomimetic soft robotic sleeve was recreated using a combination of in vitro and in silico methods. FIG. 6A illustrates the axial forces generated by the sleeve upon dynamic (pressure-control) and quasi-static (volume-control) actuation as measured by an electromechanical tester. Using a mock circulatory loop (MCL) and an FE simulation, we could predict the global hemodynamics resulting from actuation of the biomimetic soft robotic aortic sleeve (FIG. 6B-E). The FE model was adapted from the Living Heart Model (Abaqus 2018, SIMULIA, Dassault Systemes). Both the in vitro and the in silico models were tuned to approximate the porcine hemodynamics measured in vivo at baseline. In addition, the in vitro MCL loop was simplified and readapted to the magnetic resonance (MR) environment, enabling visualization of the flow and velocity vector fields upon sleeve actuation (FIG. 6F).

[0072] Both the in vitro and in silico models show consistent results with clinical literature in that actuation of the sleeve results in a drop in the effective orifice area (EOA) from baseline (BL) (FIG. 6B) and in corresponding elevations in the maximum (APmax; FIG. 6C) and mean (APmean; FIG. 6D) transaortic pressure gradients, and an increase in the peak LV pressure (LVPmax; FIG. 6E). These in vitro and in silico studies show that the soft robotic aortic sleeve can induce hemodynamic changes associated with different degrees of AS, from mild to severe. Further, the magnitude of these changes is increasingly more prominent at elevated actuation pressures. Analogously, LV pressure- volume (PV) loops obtained in silico (FIG. 6F) illustrate increases in the peak LV pressure, in agreement with clinical and computational studies of AS and pressure overload. Any discrepancy between the in vitro and in silico predictions can be attributed to slight differences in the definition of lumped-parameter elements and the dynamic response of the aortic material definition of the FE simulation with respect to the MCL set-up.

Claims

We claim:

1. A soft robotic simulator of heart function and disease which recreates the anatomy and function of specific people and patients with heart disease comprising a structure matching the anatomy of the left ventricle and of the aorta, and a patient- specific soft robotic aortic and / or ventricular heart sleeve, preferably both, recapitulating the pumping action of the heart during normal physiology and disease.

2. The simulator of claim 1 wherein the soft robotic aortic sleeve is designed to recapitulate disease such as of the aortic valve, separating the left ventricle and the aorta, the right ventricle, and other vessels connecting to the heart.

3. The simulator of claims 1 and 2 wherein the patient- specific soft robotic sleeve recapitulates the pumping action of the right ventricle and / or the left ventricle during normal physiology and / or disease.

4. The simulator of any of claims 1 to 3 wherein the simulator shows reduced pumping and / or filling function of the heart through modulation of the soft robotic heart sleeve to recreate cardiovascular conditions.

5. The simulator of any of claims 1 to 4 wherein the simulator is adapted to recreate conditions such as aortic dissection, aortic aneurysm, and mitral valve function in physiology and / or disease.

6. The simulator of any of claims 1 to 5 wherein the simulator recreates degenerative or congenital aortic valve disease and regurgitation.

7. The simulator of any of claims 1 to 6 made by three dimensional printer and / or thermal heating.

8. A method of use of the simulator of any of claims 1 to 7 to study hemodynamics, design heart pump and aortic valve prostheses, and design devices for edge-case conditions, such as complex cardiac and valvular anatomies and particularly abnormal hemodynamics, or educational training of medical students, residents, interventionalists on cardiac anatomy and function, and medical device delivery or implantation.

Citation Information

Patent Citations

  • Cardiac simulation device

    US10229615B2

  • Organosynthetic dynamic heart model

    US20210350725A1

  • Simulator, artificial heart valve, method of making artificial heart valve, arm, and predictive method

    US20230129490A1

  • Computer-controlled tissue-based simulator for training in cardiac surgical techniques

    US7798815B2

  • Apparatus for simulating a cardiovascular system

    WO2017165969A1